PE20081679A1 - Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso - Google Patents
Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de usoInfo
- Publication number
- PE20081679A1 PE20081679A1 PE2007001726A PE2007001726A PE20081679A1 PE 20081679 A1 PE20081679 A1 PE 20081679A1 PE 2007001726 A PE2007001726 A PE 2007001726A PE 2007001726 A PE2007001726 A PE 2007001726A PE 20081679 A1 PE20081679 A1 PE 20081679A1
- Authority
- PE
- Peru
- Prior art keywords
- aril
- alkyl
- phosphoinositide
- methods
- kinase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87344806P | 2006-12-07 | 2006-12-07 | |
US97725707P | 2007-10-03 | 2007-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081679A1 true PE20081679A1 (es) | 2008-12-18 |
Family
ID=39188533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001726A PE20081679A1 (es) | 2006-12-07 | 2007-12-05 | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso |
Country Status (22)
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7106296A (en) * | 1996-09-04 | 1998-03-26 | Intertrust Technologies Corp. | Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management |
CA2650290C (en) * | 2006-04-26 | 2015-11-17 | Genentech, Inc. | Pharmaceutical compounds |
TW200829594A (en) | 2006-12-07 | 2008-07-16 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
KR101460816B1 (ko) * | 2006-12-07 | 2014-11-12 | 에프. 호프만-라 로슈 아게 | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 |
ATE510841T1 (de) * | 2007-06-12 | 2011-06-15 | Hoffmann La Roche | Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase |
RU2523890C2 (ru) * | 2007-09-12 | 2014-07-27 | Дженентек, Инк. | Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения |
ES2399774T3 (es) | 2007-09-24 | 2013-04-03 | Genentech, Inc. | Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso |
JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック, インコーポレイテッド | チエノピリミジン化合物の製造方法 |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
JP5421925B2 (ja) | 2007-12-19 | 2014-02-19 | ジェネンテック, インコーポレイテッド | 5−アニリノイミダゾピリジン及び使用の方法 |
KR20100099185A (ko) | 2007-12-21 | 2010-09-10 | 제넨테크, 인크. | 아자인돌리진 및 이용 방법 |
KR20210131473A (ko) * | 2008-03-18 | 2021-11-02 | 제넨테크, 인크. | 항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
CA2729045A1 (en) * | 2008-07-31 | 2010-02-04 | Philippe Bergeron | Pyrimidine compounds, compositions and methods of use |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
AU2009304596A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1P receptors modulators |
CN102186845B (zh) * | 2008-10-17 | 2016-09-07 | 阿卡制药有限公司 | S1p受体调节剂以及它们的用途 |
PT2385832E (pt) * | 2009-01-08 | 2015-11-02 | Curis Inc | Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
KR101781654B1 (ko) | 2009-03-12 | 2017-09-25 | 제넨테크, 인크. | 조혈 악성종양의 치료를 위한 포스포이노시티드 3-키나제 억제제 화합물 및 화학요법제의 조합물 |
US8785651B2 (en) | 2009-03-24 | 2014-07-22 | Sumitomo Chemical Company, Limited | Method for manufacturing a boronic acid ester compound |
US8173650B2 (en) | 2009-05-27 | 2012-05-08 | Genentech, Inc. | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
SG182247A1 (en) * | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
CA2766151A1 (en) * | 2009-06-24 | 2010-12-29 | Genentech, Inc. | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
EP2475659B1 (en) | 2009-09-08 | 2015-10-28 | F.Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
NZ599090A (en) | 2009-09-28 | 2014-02-28 | Hoffmann La Roche | Benzoxepin pi3k inhibitor compounds and methods of use |
PE20121816A1 (es) * | 2009-10-12 | 2013-01-02 | Hoffmann La Roche | Combinaciones de un inhibidor de pi3k y un inhibidor de mek |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
SG10201500895XA (en) | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
RU2607635C2 (ru) * | 2009-11-12 | 2017-01-10 | Ф.Хоффманн-Ля Рош Аг | N-9-замещенные пуриновые соединения, композиции и способы применения |
RU2515541C2 (ru) * | 2009-11-12 | 2014-05-10 | Ф.Хоффманн-Ля Рош Аг | N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения |
RU2012139182A (ru) | 2010-02-22 | 2014-03-27 | Ф. Хоффманн-Ля Рош Аг | ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
BR112012024585A2 (pt) | 2010-03-30 | 2016-05-31 | Novartis Ag | inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas |
WO2012007493A1 (en) | 2010-07-14 | 2012-01-19 | F. Hoffmann-La Roche Ag | Purine compounds selective for ρi3κ p110 delta, and methods of use |
TW201500358A (zh) | 2010-12-16 | 2015-01-01 | Hoffmann La Roche | 三環pi3k抑制劑化合物及其使用方法 |
EP2673269A1 (en) | 2011-02-09 | 2013-12-18 | F.Hoffmann-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
US9090628B2 (en) | 2011-03-21 | 2015-07-28 | Genentech, Inc. | Benzoxazepin compounds selective for PI3K P110 delta and methods of use |
SG193563A1 (en) | 2011-04-01 | 2013-11-29 | Curis Inc | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
MY168757A (en) | 2011-05-04 | 2018-12-04 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
CN103582479A (zh) * | 2011-06-03 | 2014-02-12 | 霍夫曼-拉罗奇有限公司 | 用pi3k抑制剂化合物治疗间皮瘤的方法 |
WO2013050508A1 (en) * | 2011-10-07 | 2013-04-11 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mtor inhibitors |
CA2868392A1 (en) | 2012-05-23 | 2013-11-28 | Estelle DOUDEMENT | Compositions and methods of obtaining and using endoderm and hepatocyte cells |
CN103450204B (zh) * | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2,1-f][1,2,4]并三嗪类化合物,其制备方法及用途 |
KR101909801B1 (ko) | 2012-06-08 | 2018-10-18 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
CA2876995C (en) | 2012-07-04 | 2020-10-06 | Rhizen Pharmaceuticals Sa | Novel selective pi3k delta inhibitors |
WO2014022728A1 (en) | 2012-08-02 | 2014-02-06 | Endo Pharmaceuticals, Inc | Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer |
WO2014031429A2 (en) | 2012-08-21 | 2014-02-27 | Opko Pharmaceuticals, Llc | Liposome formulations |
MX361157B (es) | 2012-08-30 | 2018-11-28 | Hoffmann La Roche | Compuestos inhibidores de pi3k de dioxino- y oxazin-[2,3-d]pirimid ina y métodos de uso. |
AR092960A1 (es) * | 2012-10-10 | 2015-05-06 | Hoffmann La Roche | Procedimiento para preparar compuestos tienopirimidina |
EP2914260A1 (en) | 2012-10-31 | 2015-09-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
US9102689B2 (en) | 2013-05-06 | 2015-08-11 | Hoffmann-La Roche Inc. | Process for the preparation of boronic acid intermediates |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
CN105985354B (zh) * | 2015-02-09 | 2020-10-02 | 南京盖特医药技术有限公司 | 嘧啶衍生物、细胞毒性剂、药物组合物及其应用 |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
KR20180012324A (ko) | 2015-06-29 | 2018-02-05 | 에프. 호프만-라 로슈 아게 | 타셀리십을 사용하는 치료 방법 |
EP3317283B1 (en) * | 2015-07-02 | 2019-04-03 | H. Hoffnabb-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
PE20211775A1 (es) * | 2015-07-02 | 2021-09-08 | Hoffmann La Roche | Compuestos de benzoxacepina oxazolidinona y metodos de uso |
WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
CN109923117A (zh) * | 2016-11-02 | 2019-06-21 | 柯瑞斯公司 | 使用具有锌结合部分的磷酸肌醇3-激酶抑制剂的联合治疗 |
CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
CN111386264A (zh) | 2017-07-31 | 2020-07-07 | 纽约市哥伦比亚大学理事会 | 用于治疗t-细胞急性淋巴细胞白血病的化合物、组合物和方法 |
CN116003405A (zh) | 2017-09-08 | 2023-04-25 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
WO2019145177A1 (en) | 2018-01-23 | 2019-08-01 | Basf Se | Bromination of pyridine derivatives |
WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
AU2019251363B2 (en) * | 2018-04-10 | 2024-03-07 | Neuropore Therapies, Inc. | Morpholine derivates as inhibitors of Vps34 |
EP3774783A1 (en) | 2018-04-10 | 2021-02-17 | Neuropore Therapies, Inc. | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
WO2019213526A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
CA3099045A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
EP3802535B1 (en) | 2018-06-01 | 2022-12-14 | Amgen, Inc | Kras g12c inhibitors and methods of using the same |
WO2019241157A1 (en) | 2018-06-11 | 2019-12-19 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
MX2020012261A (es) | 2018-06-12 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer. |
WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
WO2020055840A1 (en) | 2018-09-11 | 2020-03-19 | Curis Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CN111205310B (zh) * | 2018-11-22 | 2023-12-19 | 上海迪诺医药科技有限公司 | 杂环稠合嘧啶衍生物、其药物组合物及应用 |
WO2020132653A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
AR117490A1 (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a |
MX2021007104A (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a. |
JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
KR20210146288A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로사이클릴 화합물 및 이의 용도 |
WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CA3140392A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
JP2022542967A (ja) | 2019-08-02 | 2022-10-07 | アムジエン・インコーポレーテツド | Kif18a阻害剤 |
EP4007756A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Kif18a inhibitors |
MX2022001296A (es) | 2019-08-02 | 2022-02-22 | Amgen Inc | Inhibidores de kif18a. |
MX2022001302A (es) | 2019-08-02 | 2022-03-02 | Amgen Inc | Inhibidores de kif18a. |
EP4045047A1 (en) | 2019-10-15 | 2022-08-24 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
EP4048671A1 (en) | 2019-10-24 | 2022-08-31 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
MX2022005357A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
CR20220243A (es) | 2019-11-04 | 2022-08-04 | Revolution Medicines Inc | Inhibidores de ras |
BR112022008858A2 (pt) | 2019-11-08 | 2022-09-06 | Revolution Medicines Inc | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer |
IL292315A (en) | 2019-11-14 | 2022-06-01 | Amgen Inc | Improved synthesis of a kras g12c inhibitory compound |
US20230192682A1 (en) | 2019-11-14 | 2023-06-22 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
CA3163680A1 (en) | 2019-12-05 | 2021-06-10 | David John O'neill | Rapamycin analogs and uses thereof |
US20230028414A1 (en) | 2019-12-16 | 2023-01-26 | Amgen Inc. | Dosing regimen of kras g12c inhibitor |
BR112022010086A2 (pt) | 2020-01-07 | 2022-09-06 | Revolution Medicines Inc | Dosagem do inibidor de shp2 e métodos de tratamento de câncer |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
CN116457358A (zh) | 2020-09-15 | 2023-07-18 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
EP4267250A1 (en) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
CN118234731A (zh) | 2021-05-05 | 2024-06-21 | 锐新医药公司 | Ras抑制剂 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
BE759493A (fr) | 1969-11-26 | 1971-05-25 | Thomae Gmbh Dr K | Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer |
DE1959403A1 (de) | 1969-11-26 | 1971-06-03 | Thomae Gmbh Dr K | Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
DE2050814A1 (de) | 1970-10-16 | 1972-04-20 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen |
US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
RO62428A (fr) | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
CH592668A5 (US06244707-20010612-C00010.png) | 1973-10-02 | 1977-10-31 | Delalande Sa | |
GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
US4196207A (en) | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
AU3262593A (en) | 1992-01-11 | 1993-08-03 | Schering Agrochemicals Limited | Biheterocyclic fungicidal compounds |
US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びpi3キナーゼ阻害剤 |
JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Pi3キナーゼ阻害剤とその製造法 |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
AUPO903897A0 (en) | 1997-09-08 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Organic boronic acid derivatives |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
HUP0100287A3 (en) | 1997-11-11 | 2003-04-28 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
DE60203260T2 (de) | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
CA2454976C (en) | 2001-07-26 | 2011-05-10 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
DE10148883A1 (de) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
AU2002357667A1 (en) | 2001-10-24 | 2003-05-06 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
WO2003035618A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
AU2002356871A1 (en) | 2001-10-30 | 2003-05-12 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
RS115904A (en) | 2002-07-10 | 2006-12-15 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused benzene derivatives |
US20050222225A1 (en) | 2002-07-10 | 2005-10-06 | Applied Research Systems Ars Holding Nv | Use of compounds for increasing spermatozoa motility |
AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
ES2217956B1 (es) | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
US7557112B2 (en) | 2004-10-08 | 2009-07-07 | Astellas Pharma Inc. | Aromatic-ring-fused pyrimidine derivative |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
WO2007122410A1 (en) | 2006-04-26 | 2007-11-01 | F.Hoffmann-La Roche Ag | Pyrimidine derivatives as pi3k inhibitors |
CA2650290C (en) | 2006-04-26 | 2015-11-17 | Genentech, Inc. | Pharmaceutical compounds |
EP2046799B1 (en) | 2006-04-26 | 2017-07-19 | Genentech, Inc. | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
PT2024372E (pt) | 2006-04-26 | 2010-09-16 | Hoffmann La Roche | Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
TW200829594A (en) | 2006-12-07 | 2008-07-16 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
KR101460816B1 (ko) | 2006-12-07 | 2014-11-12 | 에프. 호프만-라 로슈 아게 | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 |
-
2007
- 2007-12-05 KR KR1020097014134A patent/KR101460816B1/ko active IP Right Grant
- 2007-12-05 BR BRPI0717923-5A2A patent/BRPI0717923A2/pt not_active Application Discontinuation
- 2007-12-05 RU RU2009125897/04A patent/RU2468027C2/ru not_active IP Right Cessation
- 2007-12-05 NZ NZ578162A patent/NZ578162A/en not_active IP Right Cessation
- 2007-12-05 AR ARP070105449A patent/AR064155A1/es unknown
- 2007-12-05 CL CL200703520A patent/CL2007003520A1/es unknown
- 2007-12-05 AU AU2007329352A patent/AU2007329352B2/en not_active Ceased
- 2007-12-05 MY MYPI20092322A patent/MY180595A/en unknown
- 2007-12-05 US US11/951,203 patent/US7888352B2/en active Active
- 2007-12-05 JP JP2009540459A patent/JP5284977B2/ja active Active
- 2007-12-05 EP EP07854962A patent/EP2114949A1/en not_active Withdrawn
- 2007-12-05 EP EP12177885.6A patent/EP2518074B1/en active Active
- 2007-12-05 WO PCT/US2007/086543 patent/WO2008070740A1/en active Application Filing
- 2007-12-05 MX MX2009005950A patent/MX2009005950A/es active IP Right Grant
- 2007-12-05 PE PE2007001726A patent/PE20081679A1/es active IP Right Grant
- 2007-12-05 TW TW096146344A patent/TWI499420B/zh not_active IP Right Cessation
- 2007-12-05 CA CA2671782A patent/CA2671782C/en not_active Expired - Fee Related
- 2007-12-05 ES ES12177885.6T patent/ES2544082T3/es active Active
-
2009
- 2009-07-02 MA MA32069A patent/MA31146B1/fr unknown
- 2009-07-06 CR CR10915A patent/CR10915A/es unknown
- 2009-07-06 NO NO20092566A patent/NO20092566L/no not_active Application Discontinuation
- 2009-07-07 CO CO09070151A patent/CO6190615A2/es active IP Right Grant
- 2009-07-07 EC EC2009009496A patent/ECSP099496A/es unknown
-
2010
- 2010-12-23 US US12/978,106 patent/US8383620B2/en active Active
-
2013
- 2013-01-10 US US13/738,829 patent/US8993563B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081679A1 (es) | Compuestos del inhibidor de fosfoinositida 3-cinasa y metodos de uso | |
PE20060215A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
DE602005016775D1 (de) | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion | |
PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
PE20081783A1 (es) | Nuevas 2-aminooxazolinas como ligandos de taar1 | |
PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
RS51137B (sr) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
EA200601830A1 (ru) | Ортозамещённые арильные или гетероарильные амидные соединения | |
PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
PT1289955E (pt) | Piperidinas para utilizacao como antagonistas dos receptores da orexina | |
PE20070495A1 (es) | COMPUESTOS DERIVADOS DE alfa-AMINOCARBOXIAMIDA CUATERNARIOS COMO MODULADORES DE LOS CANALES DE SODIO CON APERTURA POR VOLTAJE | |
DK1765816T3 (da) | Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande | |
PE20060878A1 (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2 | |
PE20140868A1 (es) | Antagonistas trpm8 y su uso en tratamientos | |
HRP20050628A2 (en) | Substituted benzoyl derivatives uses as herbicides | |
PE20041080A1 (es) | Preparacion de medicamentos derivados de indolina sustituidos con heterociclos | |
TW200714674A (en) | Near-infrared absorbing material and use thereof | |
PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
CO5650235A2 (es) | Derivados de imidazol | |
PE20020603A1 (es) | Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |